As a partner to the U.S. Government, GRAM's newest facility was designed to increase large-scale fill and finish capacity with room to expand as demand grows.
Supports clinical trial continuity for biopharma companies during COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites
Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
Backed by Arlington Capital Partners, Grand River Aseptic Manufacturing invests in major expansion of capacity and capabilities with new fill finish facility